SUMMARY Oral amiodarone has been used to treat 21 patients with various supraventricular arrhythmias; 13 had Wolff-Parkinson-White syndrome, which was complicated by atrial fibrillation and re-entry atrioventricular tachycardia in four, and re-entry tachycardia alone in the other nine. The remaining eight patients had paroxysmal atrial fibrillation or flutter without pre-excitation. All were refractory to conventional treatment and had undergone intracardiac electrophysiological study. Fifteen have been controlled with amiodarone, this treatment proving most effective in atrial fibrillation or flutter with or without pre-excitation. Amiodarone was successful in only four of the nine patients with re-entry atrioventricular tachycardia. In two patients who responded well the drug had to be discontinued because of side effects.
Despite the abundance of drugs available for the prophylaxis of supraventricular arrhythmias there are some patients in whom conventional antiarrhythmic medications fail. While surgery is feasible in these resistant cases' it is usually reserved for life-threatening arrhythmias. Amiodarone, a benzfuran derivative originally introduced as an antianginal agent,2 has been shown to be effective in a wide variety of supraventricular arrhythmias3-5 including those complicating pre-excitation.6 I Subsequent reports, however, have not confirmed the original high success rates. 7 8 Though relatively little is known of its pharmacological behaviour, there is evidence that amiodarone is slowly absorbed,9 has a long half-life,10 and a persistent action. 5 Its antiarrhythmic action appears to differ when given intravenously as opposed to orally. 4 We investigated the action of oral amiodarone in 21 patients with supraventricular arrhythmias after electrophysiological study had been performed to define the precise nature of arrhythmia. All were evaluated during treatment by repeated 24- 20 October 1979 The repeat electrophysiological studies provided further information on the therapeutic efficacy of amiodarone and its range of action, and clarified why it failed in some.
Methods
Twenty-one patients, all with a history of recurrent palpitation, underwent intracardiac electrophysiological testing to determine the nature of their arrhythmias. The studies were performed according to our standard procedure" with modifications discussed below. Each study was performed in the fasting state after informed consent had been obtained and after all medications had been stopped for at least 72 hours.
Electrodes for stimulation and recording were positioned in the high right atrium, close to the septal cusp of the tricuspid valve, and at the apex of the right ventricle. A fourth electrode was used for atrial endocardial mapping and to allow stimulation from atrial sites other than the high right atrium. The recordings obtained were led via isolated selection boxes to the high-gain amplifiers (15 to (Fig. 1 ). In addition, these patients had orthodromic reciprocating atrioventricular tachycardia. In two patients this arrhythmia degenerated spontaneously to atrial fibrillation (Fig. 2) function was also performed to exclude hyperthyroidism17 and hypothyroidism18 known sometimes to be a complication of treatment.
Results
The findings of the limited electrophysiological study performed in group 1 three months after starting treatment are shown in single nor double premature stimuli could initiate tachycardia in the first study it was possible to induce tachycardia from the atrium with single stimuli though over a narrow zone (10 ms). In two patients the zone remained similar in width but the coupling intervals were longer; in the fourth patient (case 3) the zone was abolished. The rate of sustained re-entry tachycardia was slower in all. In three patients re-entry tachycardia terminated spontaneously after a brief period (Fig. 4) ; this had never occurred during the control study. In two patients termination occurred in the anterograde direction while in the other it occurred in the retrograde pathway.
The results of treatment with amiodarone in group 2 are shown in Table 3 . Four patients remained symptom-free on maintenance therapy, though one patient suffered a relapse of his tachycardia six weeks after his dose was decreased to 200 mg a day; he has been maintained on 400 mg a day without symptoms. Six patients had limited electrophysiological studies while on amiodarone and it was possible to initiate sustained re-entry tachycardia in all; this complemented the findings of ambulatory monitoring in the five patients who noticed no improvement. As in group 1, the tachycardia was slower and the initiation zone did not change consistently: it was wider in three and narrower in two. In the other patient two atrial extrastimuli were required to initiate tachycardia both during the control study and while on amiodarone. In one patient (case 13) in whom a more complete electrophysiological study was performed while on amiodarone the change in rate of the tachycardia was the result of lengthening of conduction time in both the atrioventricular node and the accessory pathway. The limited study on the patient who relapsed on the maintenance dose of amiodarone (case 8) showed that it was possible to initiate re-entry tachycardia but that each episode terminated with block in the retrograde limb of the circuit (Fig. 5) . The results of ambulatory monitoring performed on the patients who became asymptomatic on amiodarone showed them to be virtually free of extrasystoles, while the symptomatic group continued to have extrasystoles which often initiated tachycardia (Fig. 6 ). Of the patients in groups 1 and 2 who had reciprocating atrioventricular tachycardia and were studied while on amiodarone there was no consistent difference in the electroa) physiological changes between those who responded and those who did not. All but one in group 3 were asymptomatic after three months of treatment, the failure occurring in a patient with atrial flutter. In the other patients ambulatory monitoring showed that, in keeping with thLe clinical features, there was no sustained arrhythmia: in particular, the two patients with prolonged sinus node recovery times showed neither bradycardia nor sinus arrest. The conspicuous action of amiodarone on atrial myocardium was demonstrated in the patient in whom atrial flutter became established (Fig. 7) . In the control state the atrial rate was 330 a minute with 2:1 atrioventricular conduction (Fig. 7b) . After two weeks of treatment with amiodarone the atrial rate had fallen to 220 and 2:1 block persisted (Fig. 7c) . Two weeks later the atrial rate was even slower at 190 a minute, still showing a 2:1 atrioventricular response (Fig. 7d) . Rapid right atrial pacing induced sinus rhythm (Fig. 7e) which has been maintained on continuous treatment (Fig. 7f) .
SIDE EFFECTS
Corneal microdeposits were seen in all patients but in none was it necessary to discontinue the drug: there were no visual symptoms. The alterations in thyroid function tests reflected the interference of amiodaron.e with the metabolism of thyroid hormones20 21; all patients remained euthyroid.
Two patients stopped amiodarone because of other side effects, in both after several months of successful treatment. Case 6 had been free of arrhythmia for 23 transiently increased in the middle of the tracing by carotid sinas massage; (c) after amiodarone (two weeks): the atrial rate has fallen to 210 a minute; 2:1 atrioventricular block persists; (d) after four weeks' treatment the atrial rate has decreased further; (e) rapid atrial pacing while on amiodarone terminates the arrhythmia; sinus rhythm ensues; (f) three months after conversion to sinus rhythm, on maintenance amiodarone. the dermatitis gradually improved. In case 19 in whom paroxysmal atrial fibrillation occurred two to six times a week he had no attacks for four months while on amiodarone. He stopped treatment, however, because of persistent insomnia, restlessness, and nightmares; subsequently arrhythmias have recurred though less frequently. In other patients difficulty in sleeping, unpleasant dreams, a bitter taste in the mouth, and restlessness have been noted, but in none were the symptoms severe enough to warrant discontinuing treatment. In this study 21 patients were treated with the T-"'F::l" 1-:177 VI "I same reducing regimen of oral amiodarone. Restrictions on its use in Great Britain allow it to be tried only after conventional treatment has failed. Fifteen became asymptomatic during the first month of treatment and all but one could be maintained on 200 mg a day.
In group 1 various combinations of conventional antiarrhythmic drugs including disopyramide, quinidine, and procainamide had failed to control the symptoms or reduce the ventricular rate appreciably during atrial fibrillation. The atrial stabilising property of amiodarone was reflected in a greater resistance to the induction of atrial fibrillation, and in its spontaneous termination. The depressant action of the drug on anterograde conduction via the accessory pathway protected against the profound haemodynamic effects of atrial fibrillation in these patients.
Drugs that prevent re-entry atrioventricular tachycardia may do so by abolishing initiating extrasystoles or modifying circuit behaviour, as well as other less common factors. Modifications of circuit behaviour include abolishing the initiation zone as well as depressing conduction in either atrioventricular pathway so that any tachycardia is terminated promptly. In this series clinical benefit seemed more closely related to spontaneous termination of induced tachycardia than to changes in initiation zone from the atria. The method of termination was either by block in the retrograde direction, presumably the accessory pathway, or in the anterograde direction. While anterograde block may occur in either the atrioventricular node or His-Purkinje system, its occurrence in one patient when he was supine, but not when he was upright, suggested termination in the atrioventricular node. 29 We have examined only one method of initiation of re-entry tachycardia, albeit the most common, and it may be that other effects on the mechanism of induction of tachycardia played a part. Paradoxical aggravation of the tendency to tachycardia sometimes seen with drugs30 did not occur in any patient.
Twenty-four-hour monitoring corroborated the clinical impression of therapeutic benefit. In those patients who failed to respond, supraventricular extrasystoles persisted, often followed by paroxysms of re-entry tachycardia, while in the asymptomatic group the absence of extrasystoles was striking.
In the patients with atrial fibrillation and flutter, the absence of arrhythmias during 24- The regimen in these patients is similar to that used by other investigators8; available evidence suggests that a steady state is achieved using a single daily dose though there is no information at present on the range of blood levels achieved. While variability in the metabolism and excretion of the drug may well explain the differences in clinical efficacy, those who failed to benefit did so at the maximum dose. The selection of patients by virtue of their failure to respond to conventional antiarrhythmic agents may partly explain our lower success rate than that of others. 5 Amiodarone appears to act widely on the conducting system and myocardium and may, therefore, be particularly effective in complex arrhythmias, including some cases of paroxysmal re-entry atrioventricular tachycardia. We have found it especially effective in atrial fibrillation, and where this is associated with a rapid ventricular rate because of the Wolff-Parkinson-White syndrome amiodarone may obviate surgical treatnent. The incidence of side effects remains small but because experience is still somewhat limited close observation is recommended. Further pharnacodynamic studies are required to determine the absorption and metabolism of the drug and to ensure that it is used safely and effectively in suitable patients. 
